Welcome to our dedicated page for Assembly Bioscie SEC filings (Ticker: ASMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Assembly Biosciences, Inc. filings document a clinical-stage antiviral developer with common stock listed on the Nasdaq Global Select Market under ASMB. Recent 8-K reports furnish operating results and pipeline updates tied to investigational programs for recurrent genital herpes, chronic hepatitis delta virus and chronic hepatitis B virus, including disclosures on ABI-5366, ABI-1179, ABI-6250 and ABI-4334.
The filing record also covers the company’s collaboration revenue with Gilead, material definitive agreements, registered equity and warrant offerings, and securities registered under Section 12(b). Proxy and compensation-related filings describe governance, executive compensation, equity awards and performance-based cash bonus arrangements.
What this filing says, in plain language
Assembly Biosciences is an early-stage biotech working on several antiviral drug programs. As of June 30, 2025, it held about $24.0 million in cash and $51.0 million in marketable securities (approximately $75.0 million total). Management says that amount is not sufficient to fund operations beyond one year, and the company has substantial doubt about its ability to continue as a going concern unless it secures more funding. The company recognized collaboration revenue from Gilead of $9.6 million this quarter ($19.0 million for the six months) and has deferred revenue from that collaboration of about $53.96 million, which supports near-term work. The company reported a net loss of $10.2 million this quarter ($19.0 million six months) and used $40.2 million in cash for operations in the first half of 2025. Clinically, Assembly reported positive early human data for two long-acting herpes drug candidates (5366 and 1179), topline antiviral results for its HBV candidate (4334), and ongoing Phase 1 work for its HDV entry inhibitor (6250). These results show scientific progress but the company has no approved products and needs additional financing to continue development.
What this filing says, in plain language
Assembly Biosciences is an early-stage biotech working on several antiviral drug programs. As of June 30, 2025, it held about $24.0 million in cash and $51.0 million in marketable securities (approximately $75.0 million total). Management says that amount is not sufficient to fund operations beyond one year, and the company has substantial doubt about its ability to continue as a going concern unless it secures more funding. The company recognized collaboration revenue from Gilead of $9.6 million this quarter ($19.0 million for the six months) and has deferred revenue from that collaboration of about $53.96 million, which supports near-term work. The company reported a net loss of $10.2 million this quarter ($19.0 million six months) and used $40.2 million in cash for operations in the first half of 2025. Clinically, Assembly reported positive early human data for two long-acting herpes drug candidates (5366 and 1179), topline antiviral results for its HBV candidate (4334), and ongoing Phase 1 work for its HDV entry inhibitor (6250). These results show scientific progress but the company has no approved products and needs additional financing to continue development.